ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Last trade$10.85
Day change-$0.71 (-6.14%)
Day range$10.78 – $12.91
Volume433,490
Market cap$598M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$597.92M
Price / earnings
—
Price / book
1.52×
Price / sales
119.58×
EV / sales
96.87×
EV / EBITDA
-2.61×
Profitability
Earnings per share
-$3.27
Return on assets
-40.54%
Return on equity
-42.97%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
17.64×
Quick ratio
17.64×
Cash ratio
4.81×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$149.06M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVBP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$5M
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$5M
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$9.48M
$10.35M
$8.49M
$6.65M
$6.15M
$5.9M
$5.48M
$3.54M
Research and development
$38.9M
$42.34M
$37.62M
$32.18M
$32.17M
$27.72M
$61.29M
$20.16M
Total operating expenses
$48.38M
$52.69M
$46.11M
$38.82M
$38.32M
$33.62M
$66.77M
$23.71M
Operating income
-$43.38M
-$52.69M
-$46.11M
-$38.82M
-$38.32M
-$33.62M
-$66.77M
-$23.71M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$40.31M
-$49.89M
-$43.32M
-$35.54M
-$34.98M
-$31.4M
-$64.39M
-$20.63M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$40.31M
-$49.89M
-$43.32M
-$35.54M
-$34.98M
-$31.4M
-$64.39M
-$20.63M
Net income attributable to common shareholders
-$40.31M
-$49.89M
-$43.32M
-$35.54M
-$34.98M
-$31.4M
-$64.39M
-$20.63M
EBITDA
-$44.03M
-$52.69M
-$46.67M
-$41.85M
-$38.32M
-$33.62M
-$66.77M
-$23.71M
Basic earnings per share
-$0.81
-$1.05
-$0.96
-$0.83
-$0.83
-$0.90
-$1.90
-$0.61
Diluted earnings per share
-$0.81
-$1.05
-$0.96
-$0.83
-$0.83
-$0.90
-$1.90
-$0.61
Recent news
Company coverage with links to the original publishers.
ArriVent BioPharma announced encouraging Phase 1 results for ARR-217, a CDH17-targeted antibody-drug conjugate for gastrointestinal cancers. The drug demonstrated a 44.8% objective response rate at the 6mg/kg dose in heavily pretreated colorectal cancer patients with a manageable safety profile. The company plans to advance into Phase 1b dose optimization studies with results expected in 2027.
ArriVent BioPharma announced that initial Phase 1 safety and efficacy data for ARR-217 (MRG007), a CDH17-targeted antibody-drug conjugate for gastrointestinal cancers, will be presented as a late-breaking oral presentation at ESMO Congress 2026 in Madrid. The company will host a virtual webinar on October 26, 2026 to discuss the data and ARR-217 program.
ArriVent BioPharma received FDA IND clearance for ARR-002, a first-in-class dual-target antibody-drug conjugate targeting MUC16 and NaPi2b for ovarian and endometrial cancers. Preclinical data presented at AACR 2026 demonstrated superior efficacy and favorable tolerability compared to single-target ADCs. Phase 1 trial initiation is expected in the second half of 2026.
ArriVent BioPharma announced two preclinical poster presentations at the 2026 AACR Annual Meeting. The company will present data on firmonertinib, an EGFR inhibitor showing activity against classical and exon 20 insertion mutations with ongoing Phase 3 trials, and ARR-002, a dual-target MUC16/NaPi2b tetravalent ADC developed in partnership with Aarvik Therapeutics demonstrating superior anti-tumor activity in ovarian and endometrial cancer models.
The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.